Overview

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Dana-Farber Cancer Institute
GlaxoSmithKline
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Cyclophosphamide
Doxorubicin
Lapatinib
Liposomal doxorubicin
Paclitaxel
Trastuzumab